转移性肾细胞癌治疗进展
摘要
转移性肾细胞癌具有预后差、对传统的化疗和放疗高度抵抗的特性。但随着分子生物学的进展及肾癌发病机制的深入研究，尤其是靶向治疗药物的出现使得肾细胞癌的治疗发生了巨大变化，表现为患者无进展生存期（PFS）延长，生活质量得到提高。本文就转移性肾细胞癌的治疗进展作一综述。
出处
《国际泌尿系统杂志》
2009年第3期331-335,共5页
International Journal of Urology and Nephrology
参考文献23
-
1Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephroctomy followedby interferon alfa -2b compared with interferon alfa -2b alone for metastatic renal - cell cancer. N Engl J Med,2001,345 : 1655 - 1659.
-
2Prenen H, et al. New therapeutic developments in renal cell cancer. Crit. Rev. Oncol./Hematol. (2008).
-
3Svedman C, Sandstrom P, Pisa P, et al. A prospective Phase Ⅱ trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006,45:870- 875.
-
4At kins MB, Regan M , McDermott D. Up date on t he role of interleukin 2 and the cytokines in t he treatment of patients wit h stage Ⅳ renal ca rcinoma. Clin Ca ncer Res,2004,171:1071 - 1076.
-
5Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, intederonalfa - 2a, interleukin 2, or combination of both cytokines in patients with metastastic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007 ; 110:2468 - 2477.
-
6Schffski P, Dumez H, Clement P, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 2006;17:1185 - 1196.
-
7Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa - 2a, interleukin 2, or combination of both eytokinos in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlledtrial. Cancer, 2007, 110:2448 - 2457.
-
8Hideaki Miyake MD, Ph Da, Toshifumi Kurahashi, et al. Clinical outcome of combined immunotherapy with interferon - α and low - dose interleukine -2 forJapanese patients with metastatic renalcell carcinoma. Urologic Oncology(2008).
-
9Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program. Ann Oncolo2006, 17:32 - 33.
-
10Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol, 2005,16:523 - 530.
-
1赵晓,焦顺昌.非小细胞肺癌的免疫治疗[J].现代肿瘤医学,2011,19(10):2085-2088.
-
2傅静.姑息治疗对老年晚期胃肠道肿瘤患者生活质量的改善作用[J].中国老年学杂志,2013,33(17):4338-4339. 被引量：11
-
3沈镇宙,李鹤成.谈乳腺癌外科治疗中的热点问题[J].外科理论与实践,2004,9(2):89-91. 被引量：56
-
4阚秀.乳腺癌新辅助治疗与病理活检方式的新变化[J].中华乳腺病杂志（电子版）,2007,1(6):206-209. 被引量：1
-
5陈福军,史逸华,张晓楠,田寅.表柔比星联合紫杉醇治疗三阴性乳腺癌临床观察[J].黑龙江医药科学,2011,34(4):98-99. 被引量：7
-
6马耀梅,田爱军,张景玉.卵巢交界性肿瘤80例临床分析[J].天津医科大学学报,2009,15(2):326-328. 被引量：1
-
7李淑梅.2型糖尿病与肿瘤相关性研究进展[J].人民军医,2015,58(5):575-576.
-
8张晨辉,王志敏,王艺,黄薇.DNA甲基化与肿瘤发生发展机制研究进展[J].国外医学（肿瘤学分册）,2005,32(9):643-646. 被引量：4
-
9阚秀.对乳腺肿瘤交界性病变的新认识[J].中华乳腺病杂志（电子版）,2009,3(2):1-4. 被引量：4
-
10miR-31或将成为肺癌治疗新靶标[J].基层医学论坛,2015,0(S1):3-3.
